sandoz

Sandoz acquires global commercialisation rights to Polpharma’s multiple sclerosis biosimilar

pharmafile | September 3, 2019 | News story | Manufacturing and Production, Sales and Marketing Polpharma, Sandoz, biosimilar, multiple sclerosis, pharma 

Sandoz has revealed that it has sealed a deal with Polpharma Biologics to commercialise the latter’s proposed biosimilar version of natalizumab around the world. The biosimilar product is currently undergoing clinical testing at Phase 3 in the treatment of relapsing-remitting multiple sclerosis (RRMS). 

Under the agreement, Polpharma will handle development, manufacturing and supply responsibilities. Following approval from regulatory agencies, Sandoz will handle marketing and distribution duties across all markets exclusively. Further details of the agreement were not revealed.

Natalizumab was approved over 10 years’ ago in the disease, and a new biosimilar version will make the drug available at a reduced cost – a major concern of MS patients and their families and the most common obstacle to access in 46% of 90 countries examined in a recent report.

“Patient access to advanced medicines is important for all people diagnosed with a chronic disease, but the challenges are very pronounced for MS patients,” said Pierre Bourdage, ad interim Global Head of Biopharmaceuticals, Sandoz. “By nature, biosimilars create competition and cost savings, which are proven to make room in healthcare systems to treat more patients. With this agreement, we hope to build on our MS experience with small molecules and complex generics, and ultimately provide patients with expanded access to a DMT that healthcare systems may otherwise not be able to provide.”

Matt Fellows

Related Content

Sandoz announces deal to commercialise biosimilar ustekinumab in Europe and North America

Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung …

robina-weermeijer-ihfopazzjhm-unsplash_5

FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS

Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Latest content